Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 65% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work and whether you can afford to take the high risk of losing your money.

Open platform

Gilead To Acquire Investigational Oral Il-23R Inhibitor Hcxt-2001, Strengthening Its Inflammation Pipeline In Ibd

By Reuters News22:05 (UTC), 22 October 2026 Updated

Oct 22 (Reuters) - Gilead Sciences, Inc. GILD.O:

GILEAD TO ACQUIRE INVESTIGATIONAL ORAL IL-23R INHIBITOR HCXT-2001, STRENGTHENING ITS INFLAMMATION PIPELINE IN IBD
GILEAD TO ACQUIRE INVESTIGATIONAL ORAL IL-23R INHIBITOR HCXT-2001, STRENGTHENING ITS INFLAMMATION PIPELINE IN IBD
GILEAD - DEAL VALUED AT $1.27 BILLION IN UPFRONT CASH
GILEAD - DEAL EXPECTED TO REDUCE GAAP AND NON-GAAP EPS BY $0.79-$0.83 IN Q4 2026
GILEAD - GAINS WORLDWIDE RIGHTS TO IL-23R INHIBITOR PROGRAM INCLUDING HCXT-2001

Further company coverage: GILD.O

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.